Ariel Sacknovitz

Dr. Ariel Sacknovitz

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2024 in Epilepsia Open
Verified
Journal Article
Open access
RWRichard Wang
Richard Wang
ASAriel Sacknovitz
Ariel Sacknovitz
SVSima Vazquez
Sima Vazquez
JDJose Dominguez
Jose Dominguez
PMPatty McGoldrick
Patty McGoldrick
DBDavid E. Burdette
David E. Burdette
Objective: To describe four cases of Responsive Neurostimulation (RNS) in the bilateral pulvinar nuclei (PUL) in individuals with drug resistant epilepsy (DRE). This will show that due to widespread PUL connectivity, bilateral PUL RNS may be an option for some individuals with bilateral multifocal epilepsy.Methods: This study comprises two centers' experience with bilateral PUL RNS for DRE. Patients treated with bilateral PUL RNS at Westchester Medical Center (Valhalla, NY) and Corewell Health (Grand Rapids, MI) between the years 2019 and 2022 were analyzed and described. Presented here are methods for target selection, device programming, and clinical outcomes.Results: Two patients with Lennox–Gastaut phenotype (aged 13 and 21 years) with posteriorly dominant discharges were implanted with bilateral PUL electrodes. Additionally, two patients (aged 20 and 31 years) with independent left and right occipital bilateral multifocal seizure onsets were implanted with bilateral RNS devices targeting the ipsilateral PUL and ipsilateral occipital cortex. Subclinical and clinical seizures were captured by RNS electrocorticography (ECoG) in all patients. RNS implantation and treatment was well‐tolerated without adverse effects in all patients. Relative to baseline, two patients had 25% and 50% reduction in disabling seizures, and two patients had 71% and 100% reduction in disabling seizures. Stimulation paradigms utilized high frequency stimulation in both Lennox–Gastaut phenotype patients. Low frequency (individualized to the terminal ictal frequencies) stimulation was effective in the two bioccipital patients.Significance: RNS with electrode placement targeting bilateral PUL is safe, and no adverse effects have been attributable to the pulvinar electrode placement. PUL responsive neurostimulation is potentially effective for patients with bilateral multifocal, posteriorly dominant DRE. Both high and low frequency responsive stimulation are treatment options. Longer follow‐up will shed light on the ultimate reduction of seizure burden.Plain Language Summary: We describe four cases where stimulation devices were placed in the Pulvinar area of the thalamus (central sensory area in the brain). This is very unique and different location than where these devices are typically placed. These patients all had great outcomes with marked seizure reduction, demonstrating that this placement is both safe and effective.

1 September 2024 in Epilepsy & Behavior
Verified
Journal Article
Open access
CBCameron P. Beaudreault
Cameron P. Beaudreault
SCSharon Chiang
Sharon Chiang
ASAriel Sacknovitz
Ariel Sacknovitz
RMRobert Moss
Robert Moss
PBPaige Brabant
Paige Brabant
SWSteven Wolf
Steven Wolf
To assess the impact of vagus nerve stimulation (VNS) on quality of life contributors such as rescue medications. Using the seizure diary application SeizureTracker™ database, we examined trends in rescue administration frequency before and after the first recorded VNS magnet swipe in patients with drug-resistant epilepsy who had 1) At least one VNS magnet swipe recorded in the diary, and 2) Recorded usage of a benzodiazepine rescue medication (RM) within 90 days prior to the first swipe. A paired Wilcoxon rank-sum test was used to assess changes in RM usage frequency between 30-, 60-, 90-, 180- and 360-day intervals beginning 30 days after first magnet swipe. Longitudinal changes in RM usage frequency were assessed with a generalized estimating equation model. We analyzed data of 95 patients who met the inclusion criteria. Median baseline seizure frequency was 8.3 seizures per month, with median baseline rescue medication usage frequency of 2.1 administrations per month (SD 3.3). Significant reductions in rescue medication usage were observed in the 91 to 180 day interval after first VNS magnet swipe, and at 181 to 360 days and at 361 to 720 days, with the magnitude of reduction increasing over time. Decreases in rescue medication usage were sustained when controlling for patients who did not record rescue medication use after the first VNS magnet swipe (N=91). Significant predictors of reductions in rescue medication included baseline frequency of rescue medication usage and time after first VNS magnet swipe. This retrospective analysis suggests that usage of rescue medications is reduced following the start of VNS treatment in patients with epilepsy, and that the magnitude of reduction may progressively increase over time.

28 November 2024 in Brain Sciences
Verified
Journal Article
Open access
PDF file
HNHelen Ng
Helen Ng
EHEllen Nicole Huhulea
Ellen Nicole Huhulea
AJAnkita Jain
Ankita Jain
MFMichael Fortunato
Michael Fortunato
GSGaladu Subah
Galadu Subah
FAFawaz Al-Mufti
Fawaz Al-Mufti
Background/Objectives: Recent studies reveal an “obesity paradox”, suggesting better clinical outcomes after intracranial hemorrhage for obese patients compared to patients with a healthy BMI. While this paradox indicates improved survival rates for obese individuals in stroke cases, it is unknown whether this trend remains true across all forms of intracranial hemorrhage. Therefore, the objective of our study was to investigate the incidence, characteristics, and outcomes of hospitalized obese patients with intracranial hemorrhage. Methods: The National Inpatient Sample (NIS) database was queried for data from 2015 to 2019 to identify adult patients aged 18 years and older with a primary diagnosis of non-traumatic intracranial hemorrhage. Using International Classification of Disease 10th Edition codes, patients were stratified by BMI categories: healthy weight, overweight, class I–II obesity, and class III obesity. The cohorts were examined for demographic characteristics, comorbidities, stroke severity, inpatient complications, interventions, and clinical outcomes, including length of stay (LOS), discharge disposition, and inpatient mortality. Results: Of 41,960 intracranial hemorrhage patients identified, 13,380 (33.0%) also had an obese BMI. Class I–II obese intracranial hemorrhage patients were more likely to be of white race (OR: 1.101, 95% CI: 1.052, 1.152, p < 0.001), less likely to be female (OR: 0.773, 95% CI: 0.740, 0.808, p < 0.001), and more likely to have diabetes mellitus (OR: 1.545, 95% CI: 1.477, 1.616, p < 0.001) and hypertension (OR: 1.828, 95% CI: 1.721, 1.943, p < 0.001) in comparison to healthy-weight patients. In a matched cohort analysis adjusting for demographics and severity, intracranial hemorrhage patients with class I–II obesity had a shorter length of stay (LOS) (OR 0.402, 95% CI: 0.118, 0.705, p < 0.001), reduced inpatient mortality (OR 0.847, 95% CI: 0.798, 0.898, p < 0.001), and more favorable discharge disposition (OR 1.395, 95% CI: 1.321, 1.474, p < 0.001) compared to their healthy-weight counterparts. Furthermore, these patients were less likely to require decompressive hemicraniectomy (OR 0.697, 95% CI: 0.593, 0.820, p < 0.001). Following an analysis of individual ICH subtypes, obese subarachnoid hemorrhage (SAH) patients demonstrated reduced mortality (OR: 0.692, 95% CI: 0.577–0.831, p < 0.001) and LOS (OR: 0.070, 95% CI: 0.466–0.660, p = 0.039), with no differences in discharge disposition. Similarly, intracerebral hemorrhage patients demonstrated reduced mortality (OR: 0.891, 95% CI: 0.827–0.959, p = 0.002) and LOS (OR: 0.480, 95% CI: 0.216–0.743, p < 0.001). Other ICH subtypes showed improved discharge outcomes (OR: 1.504, 95% CI: 1.368–1.654, p < 0.001), along with decreased mortality (OR: 0.805, 95% CI: 0.715–0.907, p < 0.001) and LOS (OR: −10.313, 95% CI: −3.599 to −2.449, p < 0.001). Conclusions: Intracranial hemorrhage patients with class I–II obesity exhibited more favorable clinical outcomes than those who were of a healthy weight or overweight. Despite its association with risk factors contributing to intracranial hemorrhage, class I–II obesity was associated with improved outcomes, lending support to the existence of the obesity paradox in stroke.

12 January 2026 in Epileptic Disorders
Verified
Journal Article
Closed access
ITIsaac B. Thorman
Isaac B. Thorman
ASAriel Sacknovitz
Ariel Sacknovitz
RWRichard Wang
Richard Wang
PMPatrica Engel McGoldrick
Patrica Engel McGoldrick
MSMichael C. Schubert
Michael C. Schubert
SWSteven Wolf
Steven Wolf

13 March 2025
Verified
Book Chapter
Open access
PDF file
EMElad Mashiach
Elad Mashiach
SSSauson Soldozy
Sauson Soldozy
ASAriel Sacknovitz
Ariel Sacknovitz
AJAnkita Jain
Ankita Jain
HDHayley Donaldson
Hayley Donaldson
JSJustin Santarelli
Justin Santarelli
The evolution of advanced imaging technologies has profoundly impacted neurosurgery, enabling greater precision, safety, and improved outcomes in complex procedures. This chapter provides a comprehensive overview of key imaging modalities such as MRI, CT, fMRI, DTI, and iMRI, emphasizing their roles in neurosurgical planning, navigation, and real-time monitoring. Building on these technologies, the advent of augmented reality (AR) has introduced transformative tools that overlay digital information onto the surgical field, allowing neurosurgeons to visualize critical anatomical structures with unprecedented clarity. The integration of AR with imaging systems enhances preoperative planning, intraoperative navigation, and postoperative assessment across various neurosurgical domains, from tumor resections to minimally invasive spinal surgeries. Despite these advancements, the chapter also examines technical and practical challenges, including AR system latency, high implementation costs, and training demands. Ethical and regulatory considerations are also discussed, underscoring the need for stringent data security and alignment with healthcare regulations. The chapter concludes by exploring the potential of integrating AI-driven AR and emerging imaging modalities, highlighting the continuous innovations shaping the future of neurosurgical precision, safety, and patient care.

16 October 2024 in Brain Sciences
Verified
Journal Article
Open access
PDF file
CBCameron P. Beaudreault
Cameron P. Beaudreault
RWRichard Wang
Richard Wang
CMCarrie R Muh
Carrie R Muh
ARAshley Rosenberg
Ashley Rosenberg
AFAbigail Funari
Abigail Funari
SCSangmi Park & Sangmi Chung
Sangmi Park & Sangmi Chung
Background: Cell-based therapies for drug-resistant epilepsy using induced pluripotent stem cell-derived inhibitory interneurons are now in early-phase clinical trials, building on findings from trials in Parkinson’s disease (PD) and Huntington’s disease (HD). Graft rejection and the need for immunosuppressive therapy post-transplantation pose potential barriers to more epilepsy patients becoming potential candidates for inhibitory interneurons transplantation surgery. Objectives: The present literature review weighs the evidence for and against human leukocyte antigen (HLA)-mediated graft rejection in PD and HD and examines the potential advantages and drawbacks to five broad approaches to cell-based therapies, including autologous cell culture and transplantation, in vivo reprogramming of glial cells using viral vectors, allogeneic transplantation using off-the-shelf cell lines, transplantation using inhibitory interneurons cultured from HLA-matched cell lines, and the use of hypoimmunogenic-induced pluripotent stem cell-derived inhibitory interneurons. The impact of surgical technique and associated needle trauma on graft rejection is also discussed. Methods: Non-systematic literature review. Results: While cell-based therapies have enjoyed early successes in treating a host of central nervous system disorders, the immunologic reaction against surgical procedures and implanted materials has remained a major obstacle. Conclusions: Adapting cell-based therapies using iPSC-derived inhibitory interneurons for epilepsy surgery will similarly require surmounting the challenge of immunogenicity.